Tempus expands multi-year collaboration with Moderna, Merck on V940 melanoma vaccine commercialization support
Bitget2026/10/07 12:30Tempus expanded a multi-year collaboration with Moderna, Merck to support potential commercialization of personalized cancer vaccine intismeran autogene (V940/mRNA-4157). Scope covers sample collection logistics for tumor tissue and blood required for next-generation sequencing, a key step in individualized therapy workflows. Tempus is set to provide sequencing services, subject to regulatory approvals, to support therapy design and manufacturing. Program targets patients with completely resected stage IIB-IV melanoma, with evaluation in other cancer types. Financial terms were not disclosed. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261007586639) on October 07, 2026, and is solely responsible for the information contained therein.
- Tempus expanded a multi-year collaboration with Moderna, Merck to support potential commercialization of personalized cancer vaccine intismeran autogene (V940/mRNA-4157).
- Scope covers sample collection logistics for tumor tissue and blood required for next-generation sequencing, a key step in individualized therapy workflows.
- Tempus is set to provide sequencing services, subject to regulatory approvals, to support therapy design and manufacturing.
- Program targets patients with completely resected stage IIB-IV melanoma, with evaluation in other cancer types.
- Financial terms were not disclosed.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SNT Holdings, Related Party Raise Combined Stake in SNTEnergy to 55.75% From 52.75%
Cold wave and rising fuel costs drive electricity prices in northeastern Japan and Tokyo to a four-year high
Japan's spot electricity prices surged to multi-year highs over the weekend.
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.
Canaccord Genuity: Lowers Oklo's target price to $66
Crypto prices
More
